- In June 2024, SPI Pharma, Inc. announced a partnership with Inimmune Corp. to advance the commercialization of new vaccine adjuvant solutions. This alliance focuses on developing adjuvants that can improve immune responses and broaden protection against various diseases
- In March 2024, Croda International Plc partnered with the Access to Advanced Health Institute (AAHI) to develop innovative adjuvant formulations. This collaboration aims to enhance vaccine efficacy and stability, particularly in emerging markets
- In February 2024, TollereBio entered into a licensing agreement with the University of Maryland, Baltimore, to commercialize a unique vaccine adjuvant technology based on bacterial enzymatic combinatorial chemistry (BECC). This technology aims to produce cost-effective adjuvants for both therapeutic and prophylactic vaccines
- In February 2023, Adjuvance Technologies Inc. introduced ATX-M102, a saponin-based adjuvant designed for use in various vaccines, including those targeting infectious diseases, cancer, and allergies. Clinical trials have shown it to be safe and effective, marking a significant step in adjuvant innovation
- In January 2023, Dynavax Technologies Corporation partnered with Sanofi Pasteur to develop and commercialize CpG 1018, a synthetic Toll-like receptor 9 agonist. This adjuvant has demonstrated the ability to boost immune responses in influenza vaccine candidates, aiming to produce more effective and affordable vaccines
